Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Intratumour heterogeneity"'
Autor:
Ryohei Yoshitake, Hitomi Mori, Desiree Ha, Xiwei Wu, Jinhui Wang, Xiaoqiang Wang, Kohei Saeki, Gregory Chang, Hyun Jeong Shim, Yin Chan, Shiuan Chen
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Background Intratumour heterogeneity is a hallmark of most solid tumours, including breast cancers. We applied spatial transcriptomics and single‐cell RNA‐sequencing on patient‐derived xenografts (PDXs) to profile spatially resolved ce
Externí odkaz:
https://doaj.org/article/c912d0814431403cb39c58c440c17054
Publikováno v:
JHEP Reports, Vol 5, Iss 6, Pp 100754- (2023)
Background & Aims: Intratumour heterogeneity (ITH) fosters the vulnerability of RNA expression-based biomarkers derived from a single biopsy to tumour sampling bias, and is regarded as an unaddressed confounding factor for patient precision stratific
Externí odkaz:
https://doaj.org/article/f72d09239bb841c88fa93095ab41f56b
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
Autor:
Mieke R. Van Bockstal, Marie Colombe Agahozo, Ronald van Marion, Peggy N. Atmodimedjo, Hein F. B. M. Sleddens, Winand N. M. Dinjens, Lindy L. Visser, Esther H. Lips, Jelle Wesseling, Carolien H. M. van Deurzen
Publikováno v:
Molecular Oncology, Vol 14, Iss 4, Pp 671-685 (2020)
Intratumour heterogeneity fuels carcinogenesis and allows circumventing specific targeted therapies. HER2 gene amplification is associated with poor outcome in invasive breast cancer. Heterogeneous HER2 amplification has been described in 5–41% of
Externí odkaz:
https://doaj.org/article/bab2d6a1b653450da771b3f429430417
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Modern cancer treatment strategies aim to target tumour specific genetic (or epigenetic) alterations. Treatment response improves if these alterations are clonal, i.e. present in all cancer cells within tumours. However, the ident
Externí odkaz:
https://doaj.org/article/f583a33bade54775bdaee56c92172c00
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Christina S. Fjeldbo, Tord Hompland, Tiril Hillestad, Eva-Katrine Aarnes, Clara-Cecilie Günther, Gunnar B. Kristensen, Eirik Malinen, Heidi Lyng
Publikováno v:
EBioMedicine, Vol 57, Iss , Pp 102841- (2020)
Background: Emerging biomarkers from medical imaging or molecular characterization of tumour biopsies open up for combining the two and exploiting their synergy in treatment planning of cancer patients. We generated a paired data set of imaging- and
Externí odkaz:
https://doaj.org/article/3d65c49175784f69a4be020b61c5e15f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Deborah R. Caswell, Charles Swanton
Publikováno v:
BMC Medicine, Vol 15, Iss 1, Pp 1-9 (2017)
Abstract Background The advent of rapid and inexpensive sequencing technology allows scientists to decipher heterogeneity within primary tumours, between primary and metastatic sites, and between metastases. Charting the evolutionary history of indiv
Externí odkaz:
https://doaj.org/article/8c7c15f753004243ae0a50e8f88252f6
Autor:
Schmelz, Karin, Toedling, Joern, Huska, Matt, Cwikla, Maja C., Kruetzfeldt, Louisa-Marie, Proba, Jutta, Ambros, Peter F., Ambros, Inge M., Boral, Sengül, Lodrini, Marco, Chen, Celine Y., Burkert, Martin, Guergen, Dennis, Szymansky, Annabell, Astrahantseff, Kathy, Kuenkele, Annette, Haase, Kerstin, Fischer, Matthias, Deubzer, Hedwig E., Hertwig, Falk, Hundsdoerfer, Patrick, Henssen, Anton G., Schwarz, Roland F., Schulte, Johannes H., Eggert, Angelika
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
Intratumour heterogeneity is a major cause of treatment failure in cancer. We present in-depth analyses combining transcriptomic and genomic profiling with ultra-deep targeted sequencing of multiregional biopsies in 10 patients with neuroblastoma, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::885aa51bcb35496e29847133fcf2a6b5
https://doaj.org/article/2390ab09b04a41c28245bac3ed08f2c9
https://doaj.org/article/2390ab09b04a41c28245bac3ed08f2c9
Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification
Autor:
Marie Colombe Agahozo, Lindy L. Visser, Winand N.M. Dinjens, Jelle Wesseling, Ronald van Marion, Esther H. Lips, Carolien H.M. van Deurzen, Peggy N. Atmodimedjo, Hein F.B.M. Sleddens, Mieke Van Bockstal
Publikováno v:
Molecular Oncology
Molecular Oncology, 14(4), 671-685. John Wiley & Sons Ltd.
Molecular oncology, Vol. 14, no.4, p. 671-685 (2020)
Molecular Oncology, Vol 14, Iss 4, Pp 671-685 (2020)
Molecular Oncology, 14(4), 671-685. John Wiley & Sons Ltd.
Molecular oncology, Vol. 14, no.4, p. 671-685 (2020)
Molecular Oncology, Vol 14, Iss 4, Pp 671-685 (2020)
Intratumour heterogeneity fuels carcinogenesis and allows circumventing specific targeted therapies. HER2 gene amplification is associated with poor outcome in invasive breast cancer. Heterogeneous HER2 amplification has been described in 5–41% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5cbecb1c8d61d18905072c1bf7c6cd4
http://europepmc.org/articles/PMC7138394
http://europepmc.org/articles/PMC7138394